Gut-targeted treatments for Parkinson's disease have drawn attention for years, but a new pooled analysis suggests their clearest benefit so far is in the bowel, not in the shaking, stiffness and slowness that define the disease.
The work is a systematic review and network meta-analysis, published in Frontiers in Microbiology in 2026. It pulls together results from 19 randomized controlled trials, which involved 1,156 people with Parkinson's disease. Randomized trials are the strongest design for testing a treatment. A network meta-analysis lets researchers compare several treatments at once, even when the trials did not test them against each other.
The treatments were probiotics, synbiotics (probiotics combined with a food source for them) and fecal microbiota transplantation, or FMT, which transfers gut bacteria from a donor. They were compared with placebo and with routine care. Routine care meant staying on stable doses of standard Parkinson's drugs. The authors searched databases from their start through April 1, 2026.
Probiotics came out ahead on one measure. According to the paper, they increased the frequency of spontaneous bowel movements compared with placebo (mean difference 1.93, 95% confidence interval 0.23 to 3.64). Among trials that gave treatments by mouth, probiotics (mean difference 2.01) and synbiotics (mean difference 1.23) both increased bowel movement frequency. The authors rated the certainty of the oral probiotic result as moderate. Constipation matters in Parkinson's. The study's introduction notes that gut problems, particularly constipation, may appear before motor symptoms do.
Movement symptoms told a different story. No active treatment significantly improved scores on the MDS-UPDRS III, a clinician-rated measure of motor function, compared with placebo. Synbiotics and FMT ranked higher than the other options in the authors' ranking analysis. But the authors say those rankings should be considered exploratory. Evidence for motor function and quality of life was rated low to very low certainty.
That means these trials cannot show that the treatments help movement, and they cannot rule it out either. The authors call for larger head-to-head randomized trials.
The review also notes why results have been inconsistent. Trials differ in microbial strains, doses, delivery routes and treatment length. A separate 2025 review in Minerva Gastroenterology, summarized only through its abstract, points the same way. It reports that fewer butyrate-producing bacteria have been linked to Parkinson's progression, and that early microbiome-based treatments show preliminary benefit. It also stresses that varied methods and the difficulty of proving cause remain major limits.
Only the abstract and page text of the main study were available for this article. Details beyond them, such as safety reporting and individual trial designs, are not covered here.
Larger trials that compare probiotics, synbiotics and FMT directly, using consistent strains, doses and durations, and that measure motor symptoms and quality of life. Anyone considering a probiotic, synbiotic or FMT for Parkinson's should not start or stop any treatment without talking to their own clinician.
Sources: Frontiers in Microbiology (2026), Frontiers in Microbiology
Keep reading on this subject
The microbiome · Brain health & cognition